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Abstract 
Variations in levels of apolipoprotein E (ApoE) have been tied to the risk and progression of 
Alzheimer’s disease (AD). Our group has previously compared and contrasted the promoters of 
the mouse and human ApoE gene (APOE) promoter sequences and found notable similarities 
and significant differences that suggest the importance of the APOE promoter’s role in the 
human disease. We examine here three specific single–nucleotide polymorphisms within the 
human APOE promoter region, specifically at −219 (G/T), −427 (T/C), and at −491 (A/T) 
upstream from the +1 transcription start site. The −219 and −491 polymorphic variations have 
significant association with instance of AD, and −491AA has significant risk even when 
stratified for the APOEε4 allele. We also show significant effects on reporter gene expression in 
neuronal cell cultures, and, notably, these effects are modified by species origin of the cells. The 
−491 and −219 polymorphisms may have an interactive effect in addition to any independent 
activity. DNA–protein interactions differ between each polymorphic state. We propose SP1 and 
GATA as candidates for regulatory control of the −491 and −219 polymorphic sites. This work’s 
significance lies in drawing connection among APOE promoter polymorphisms’ associations 
with AD to functional promoter activity differences and specific changes in DNA–protein 
interactions with cell culture-based assays. Taken together, these results suggest that APOE 
expression levels are a risk factor for AD irrespective of APOEε4 allele status. 
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Introduction 
Alzheimer’s disease (AD) is the leading cause of dementia among the elderly (Hebert et al. 2003; 
Lahiri 2004a). A known risk factor for AD is the apolipoprotein E (ApoE) ε4 genotype (Corder 
et al. 1993; Lahiri 2004a; Saunders et al. 1993). In addition to coding sequence polymorphisms, 
three promoter polymorphisms have been identified on the ApoE gene (APOE) with potential 
influence on sporadic AD (Artiga et al. 1998b; Bullido et al. 1998; Lambert et al. 2002). These 
polymorphisms reside at −491 (rs449647, A/T), −427 (rs769446, T/C), and −219 (TH1/E47cs, 
rs405509, G/T) (Lambert et al. 2002; Lambert et al. 2004). It has been reported that the −491AA 
genotype confers an independent risk for developing AD (Lambert et al. 2002; Lambert et al. 
2004), as has likewise been stated for the −219T allele (Lambert et al. 2002; Lambert et al. 
2004), although the field is not unanimous, since reports that failed to find an AD association 
with the −491 (Thome et al. 1999; Toji et al. 1999) or the −219 (Tycko et al. 2004; Zurutuza et 
al. 2000) loci are also in the literature. Meta–analysis of 38 studies indicated an AD–associated 
OR (95% CI) of 0.73 (0.64, 0.82) for the T allele at −491; meta–analysis of 13 studies showed an 
OR (95% CI) of 0.86 (0.68, 1.09) for the C allele at −427; and meta–analysis of 20 studies 
revealed an OR (95% CI) of 0.73 (0.68, 0.78) for the G allele at −217 (Bertram et al. 2007). 
While important work has been done in characterizing effects of individual single nucleotide 
polymorphisms (SNPs) on promoter activity (Artiga et al. 1998b; Ramos et al. 2005), evidence 
exists that these polymorphisms may function in vivo as haplogroups, with pathogenic influence 
beyond independent effects they may exert (Parra-Bonilla et al. 2003). 
We have previously characterized the 5’–flanking regions of the APOE genes of mouse 
(Lahiri et al. 2002) and human (Du et al. 2005) and determined important structural and 
functional differences between them, including the presence of functional promoter regulatory 
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domains HuA (“human A”) through HuE and MoA (“mouse A”) through MoD (Maloney et al. 
2007). While the mouse sequence was determined to share homology at the −219 polymorphic 
site, no homology was found between human and mouse at either of the other two sites (−491 
and −427). This notable structural difference between two species suggests an important role for 
the APOE promoter in the pathogenesis of AD. Therefore, we continued our work on the APOE 
promoter with the human sequence. 
Healthy and AD–diagnosed subjects were genotyped for the APOE ε2/ε3/ε4 allele and for 
each of the two alleles at −491, −427, and −219. Statistically significant associations were 
observed with homozygosity for the A allele at the −491 promoter polymorphism and with 
homozygosity for the T allele at the −219 SNP. After stratification for presence of the ε4 allele, 
the −491AA genotype retained significance as a risk factor for AD in the ε4–negative population, 
whereas no such an association was still detected in the ε4–positive group. Regarding the 
−219TT genotype, this same analysis reveals that the association is lost in both groups after 
stratification. 
To investigate activity and potential interactions of the three APOE promoter SNPs, we 
constructed eight different clones containing 1.4 kilobases (kb) of the APOE 5’–flanking region. 
These clones included all currently known polymorphic variants at each of three locations fused 
to the chloramphenicol acetyltransferase (CAT) reporter gene. The clones were transfected into 
human SK–N–SH neuroblastoma (NB) and rat pheochromocytoma (PC12) neuronal cells and 
resulting reporter levels were analyzed. We determined that the −491 A/T polymorphism exerted 
independent effect on reporter protein levels in both NB and PC12 cells. The −219 G/T 
polymorphism had significant independent effects in NB cells but not in PC12 cells. Multiple 
ANOVA analysis of data indicated a significant interaction between the effects exerted by the 
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polymorphisms at −491 and −219 in PC12 cells but not in NB cells. The −427 polymorphism did 
not have any significant effect on reporter gene product levels. In addition, each polymorphic 
state displayed differential DNA–protein interactions as revealed from electrophoretic mobility 
shift assay and Southwestern blotting experiments. Taken together, our work partially confirms 
the proposed existence (Parra-Bonilla et al. 2003) of a haplogroup of the −491 and −219 
polymorphisms of the APOE promoter. Furthermore, the −491 polymorphism was confirmed as 
significantly altering APOE promoter activity independently of other polymorphisms in two cell 
lines from two different species while the −219 polymorphism only had this effect in human NB 
cells. 
Materials and Methods: 
Reagents. Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO) and 
were of “molecular biology” or “analytic” quality. Enzymes were purchased from Roche 
(Indianapolis, IN). Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). 
Cell lines. Rat pheochromocytoma (PC12) and human SK–N–SH neuroblastoma (NB) cell 
cultures were acquired from ATCC and routinely cultured according to ATCC instructions in our 
laboratory (Ghosh et al. 2000). Tissue culture reagents were obtained from Invitrogen. 
Preparation of nuclear extracts. Nuclear extracts from NB and PC12 cell lines and from mouse 
brain tissue were obtained commercially (Active Motif, Carlsbad CA). 
Populations. The study population was recruited from the Alzheimer’s disease research center at 
Mayo Clinic, Rochester, MN. Samples from all subjects were collected under IRB approved 
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protocols with informed consent signed by the individuals or next of kin. Patients were 
diagnosed with probable AD according to NINCDS–ADRDA criteria. DNA was extracted from 
peripheral blood cells using standard protocols. All sample DNA’s were plated in 96–well plates 
with cases and controls being randomly plated together. 
 The series comprised 310 sporadic late–onset AD cases (67% female, 15% autopsy 
confirmed) with mean age of 83.2±8.0 and mean age at onset of 77.6±8.0. Controls for this 
cohort included 425 individuals (68% female; 5% autopsy confirmed) with mean age of 
83.3±7.1. 
Genotyping of patient DNA for APOE promoter SNP status. DNA extraction and APOE 
genotyping were performed according to published methods with minor modifications (Artiga et 
al. 1998b; Crook et al. 1994; Lahiri and Nurnberger 1991; Lambert et al. 1998). A summary of 
primers, conditions, and genotyping details can be found in Table I. 
Construction of APOE promoter polymorphism CAT reporter fusion clones. Genotyped 
DNA was isolated via PCR from human subjects using oligomers that inserted HindIII, KpnI, 
and XhoI linkers at the ends of a 1.4kb APOE promoter/intron fragment (Fig. 1A). The fragment 
was inserted into the HindIII and XhoI sites of pBluescript SK (−) (Fig. 1B). Clones 
corresponding to six of eight possible SNP polymorphism combinations were constructed in this 
fashion. Two haplotypes (T/C/T and T/C/G) did not appear in our sample population (data not 
shown). These two clones were derived by site–directed mutagenesis of the corresponding 
−427T/−219T or −427T/−219G haplotype clones using the Transformer site–directed 
mutagenesis kit (Clontech, Mountain View, CA). The pBluescript–backbone clones were 
digested with KpnI and XhoI and 1.4kb APOE fragments were cloned into pGL3 (Promega) (Fig. 
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1C). Preliminary attempts to perform luciferase–based assays produced unacceptable noise due 
to well–to–well variation and cross talk from various neighboring wells. Therefore, the pGL3–
backbone clones were digested with KpnI and XhoI. The 1.4kb APOE promoter fragment band 
was purified from each and subcloned into the KpnI and XhoI sites of vector pCAT3Basic 
(Promega) to produce eight fusion clones, containing each possible permutation of the SNP 
variants, driving the CAT reporter coding sequence (Fig. 1D) to produce eight different 
polymorphic haplotype clones (Fig. 1E). 
DNA transfection of APOE promoter polymorphism-CAT reporter constructs in NB and 
PC12 cell cultures. NB and PC12 cell cultures were transfected with empty vector pCAT3Basic 
or one of eight polymorphic APOE promoter–CAT reporter constructs by Lipofectamine and the 
associated Plus Reagent (Invitrogen), as described previously (Ghosh et al. 2000). Transfection 
was carried out in 2–3x106 cells per 60mm plate in triplicate, with 2.7 µg of CAT reporter clone 
plasmid DNA. To monitor transfection efficiency, cells were cotransfected with 0.3µg 
pSVβGAL (Promega) under the same conditions. Following transfection, cells were harvested, 
extracts prepared, protein concentration determined, CAT reporter protein levels were measured 
by enzyme–labeled immunosorbent assay (ELISA) and β–galactosidase (β–GAL) activity was 
assayed colorimetrically (Ghosh et al. 2000). Presence of β–GAL levels above background was 
taken as indicative of successful transfection. 
Reporter gene expression and data analysis. Activity of the reporter gene for all fusion clones 
was checked by measuring reporter protein levels by ELISA, using a commercial kit (Roche, 
Indianapolis, IN). Reporter protein level was adjusted to total protein in extract. Assays were 
done in linear range from three transfection experiments. Results from adjusted reporter gene 
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activity were statistically analyzed with the SAS System 9.1 statistical analysis package (SAS 
Institute, Cary, NC) via three–way ANOVA followed by Waller–Duncan multiple range test or 
Student’s t test. 
Electrophoretic mobility shift assay (EMSA) of APOE polymorphisms. Oligomers reflecting 
the −491 A/T and −219 G/T SNPs (Table II) were designed according to Artiga et al (Artiga et 
al. 1998b) and commercially synthesized (Invitrogen) as single stranded oligomers. Oligomers 
were annealed and labeled with [γ32P]–ATP (GE Healthcare, Piscataway, NJ) via polynucleotide 
kinase (Roche). The assay was carried out with 10,000 cpm of probe (20–50 ng) and 10 µg of 
nuclear extracts. Nuclear protein extracts from NB and PC12 cells were incubated in 19 µl of 
EMSA binding buffer (10 mM Tris–HCl, pH7.5; 50 mM NaCl; 0.5 mM DTT, 5% glycerol; 
0.05% Triton X–100; 100 µg/ml poly dI:dC) at 8°C for 15 min. In the “Competition–EMSA” 
assay, excess (150x molar concentration) unlabeled oligomer was added in a volume of 1µl and 
reactions were incubated at 8°C for 15 minutes. Radioactive probe was added (10,000 CPM) and 
reactions further incubated at 8°C for 30 min. The samples were mixed with loading dye (50% 
glycerol, 1mM EDTA), and the products of the binding reaction were separated on a 
nondenaturing polyacrylamide gel (5%) in 1× TGE buffer (50 mM Tris, pH 8.5, 380 mM 
glycine, and 2 mM EDTA). The gel was dried and exposed to X–ray film with intensifying 
screen for fluorography at −70°C. Free unbound oligonucleotides ran at the bottom of the gel; 
different protein–DNA complexes were detected as mobility–retarded bands. Experiments were 
repeated with duplicate oligomers obtained commercially (IDT Technology, Coralville, IA). 
Southwestern blotting of multiple nuclear extracts with polymorphic oligomers. Nuclear 
extracts from NB and PC12 cells, 10 µg total protein, each, were run in duplicate sets on 10% 
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SDS–PAGE in a MiniProtean gel apparatus (BioRad) as described previously (Lahiri et al. 
1994). Samples were transferred via tank blotting to 0.45 µm nitrocellulose membranes in 25 
mM of Tris–Cl, pH 7.4, 190 mM glycine, 1 mM EDTA and 0.01% SDS. Membrane was cut into 
two parts and each was probed individually by southwestern blotting (Lahiri 1998). Briefly, 
proteins bound on the filter were renatured by incubation at 4°C for 24 h in 15 ml of 10 mM 
HEPES, pH 7.9, 50 mM NaCl, 0.1 mM EDTA, 10 mM MgCl2, 1 mM DTT, 10% glycerol and 
5% milk powder (Carnation Non–fat). For DNA binding, the blocking solution was replaced by 
15 ml binding buffer (same composition as above except only 0.25% milk powder was used) 
with 10 µg poly dI•dC and 20 ng of each probe (specific activity 0.8 to 1.0×106 CPM/ng) and 
was gently shaken at 4°C for 18 h. Filters were washed twice at room temperature in 50 ml of the 
binding buffer (without probe and poly dI•dC) for 15 min. each and exposed to X–ray film. 
Results: 
Genotype frequencies of APOE polymorphisms and AD risk. The distribution of alleles and 
genotypes was consistent with that expected under Hardy–Weinberg equilibrium (−491: p>0.5; 
−427: p>0.9; −219: p>0.2; coding region: p>0.6). Table III summarizes the results of the genetic 
analysis. As expected, the strongest association was found with the polymorphism at the coding 
region, possession of at least one copy of the ε4 allele significantly increased the risk for the 
disease (OR=4.29; CI95%=[3.16–5.82]). Additionally the reported protective effect of the ε2 
allele was also seen (χ 12=16.29, p=5.43x10−5; OR=0.40 CI95%=[0.25–0.63]; ε2 allele carriers vs. 
non–carriers). In addition to this, statistically significant associations of similar magnitude were 
observed with homozygosity for the A allele at the −491 promoter polymorphism (χ 12=7.57, 
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p=0.006; OR=1.55 CI95%=[1.13–2.12]) and with homozygosity for the T allele at the −219 SNP 
(χ 12=8.67, p=0.003; OR=1.64, CI95%=[1.18–2.18]). 
 After stratification for presence of the ε4 allele, the −491AA genotype was still a risk 
factor for AD in the ε4-negative population (χ 12=4.62, p=0.032; OR=1.58, CI95%=[1.04–2.40]) 
whereas no such an association was still detected in the ε4-positive group. Regarding the 
−219TT genotype, this same analysis reveals that the association was lost in both groups after 
stratification. 
 Finally, logistic regression was used to detect interactions between the different 
polymorphisms, as well as age or sex. In this case, only the coding region polymorphism was 
still associated with the risk for AD (p<10-4; OR=1.90, CI95%=[1.64–2.22]). 
Sequencing of APOE promoter with SNP regions. PCR of human genomic DNA samples with 
specific primers produced a 1.4kb fragment (Fig. 1). Excepting for the specific locations of the 
three SNPs, DNA sequences derived within our sample were 100% homologous to GenBank 
sequence #M10065. 
Reporter expression levels of APOE promoter polymorphisms in NB and PC12 cells. To 
investigate effects of the three APOE promoter polymorphisms at −491, −427, and −219 on 
promoter activity, NB and PC12 cell cultures were independently transfected with eight APOE 
promoter polymorphic clones, as described herein. Cells were also cotransfected with pSVβGAL 
to monitor transfection efficiency. Cells were collected and extracts used to measure total protein 
and for ELISA of reporter gene protein. Correlation analysis of raw data revealed that a strong 
confounding correlation (r = 0.628, p = 0.001) existed between ELISA signal of CAT reporter 
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protein and activity of β–galactosidase (Table IV). Therefore, statistical analysis was continued 
with CAT reporter protein signal adjusted by total protein. In all cases, APOE promoter–reporter 
gene fusion clones had significantly higher reporter protein levels than did pCAT3Basic vector 
backbone. Analysis by each individual polymorphic site revealed that the −491 polymorphism 
drove significant independent difference in reporter protein levels in both cell lines (Fig. 2A and 
5A). The −427 polymorphism (Fig. 2B and 5B) showed no significant differences in activity 
between either allele. The −219 polymorphism had a significant difference of reporter levels in 
NB cells (Fig 1C) but not in PC12 cells (Fig. 5C). 
 Multiple ANOVA (Tables V and VI) indicated no significant interaction between any 
two–polymorphism effects in NB cells (Fig. 3). However, in PC12 cells (Fig. 6), there was a 
significant interaction between −491 and −219 (p < 0.0001). This interaction remained 
significant when ranked reporter protein levels were subject to ANOVA (Table VIB). The −219 
variants had opposite (and significant at kratio = 100) effects depending upon the particular −491 
variant each was associated with (Fig. 6B). The −491A/−219G double polymorphism had 
significantly lower reporter protein levels than did −491A/−219T. On the other hand, 
−491T/−219G had significantly higher reporter protein levels than did −491T/−219T. 
 No significant three–way interaction appeared in NB cells. A significant three–way 
interaction (p = 0.005) was detected in PC12 cells by multiple ANOVA. However, this three–
way interaction (Fig. 7) was weak at best. While some individual polymorphic triads 
significantly differed from others (Fig. 7A), comparing the three–way interaction “sliced” 
according to the state of the −427 polymorphism showed little difference that specifically 
depended upon whether or not −427 was “C” or “T” (Fig. 4B, 7B). 
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Electrophoretic mobility shift assays (EMSA) of APOE polymorphisms. Given that the −427 
T/C polymorphism produced no significant results in our constitutive expression assay, it was 
excluded from EMSA analysis. Double–stranded oligomers corresponding to the −491 A/T and 
−219 G/T polymorphisms were obtained from two different sources and used to perform EMSA 
and competitive EMSA twice, as described herein. Reactions were performed with nuclear 
extracts from NB and PC12 cells. Competition was against unlabeled corresponding 
polymorphic oligomer and against alternate polymorphic oligomer for the same site in both NB 
and PC12 extracts. Additionally, in NB extracts, the −491A and T probes were competed against 
unlabeled −219G oligomer, and the −219G and T probes were competed against unabeled 
−491A oligomer, both as "negative controls" for the competition. It is likely that differences 
between DNA–protein interactions at the −491 polymorphic locus may be more quantitative 
(altered affinity for the same transcription factors) in nature than qualitative in NB nuclear 
extracts. 
 When NB nuclear extracts were probed (Fig. 8A), differences appeared between the 
−491A and −491T polymorphisms (lanes 1–8) and between the −219G and −219T 
polymorphisms (lanes 9–16). Both of the −491 variants had two DNA interaction bands (I, II) 
with NB nuclear extracts. However, interaction at band “I” was much stronger than at band “II” 
for −491A, while interaction was approximately equal between the two bands for −491T. 
Competition with 150x molar excess unlabeled oligomers indicated that the −491A and T 
variants equally competed against radiolabeled −491A, while unlabeled −491T competed more 
efficiently against labeled −491T than did unlabeled −491A. There was also some limited 
competition of unlabeled −219G with both of the −491 probes. EMSA of the −219 
polymorphisms also showed differences between the two variants. When probing with −219G, 
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three interactions (III, IV, VII) appeared. When probing with −219T, two different interactions 
(V, VI) were present. Competition of labeled −219G with unlabeled −219G caused reduction in 
signal for all bands, but competition was incomplete. Competition with unlabeled −219T did not 
reduce any signal. Competition of labeled −219T with unlabeled −219T reduced the signal at 
“IV” and “VI”. There was little to no signal reduction when competing with unlabeled −219G. 
Competition with unlabeled −491A had no effect on either labeled probe. Differences in DNA–
protein interactions at the −291 locus are qualitative in NB nuclear extracts, indicating a change 
in specific transcription factor binding. 
 EMSA assay with the −491 probes and PC12 nuclear extracts (Fig. 8B, lanes 1–6) 
resembled the EMSA pattern found when NB nuclear extracts were probed with the same 
oligomers. Two bands (I, II) appeared in uncompeted reactions (lanes 1, 4), although “II” was 
either very weak or absent with the −491A probe. Both −491 unlabeled oligomers strongly 
competed against labeled −491A (lanes 2, 3), while competition was not as complete when 
unlabeled oligomers were competed against labeled −491T (lanes 5, 6). While no specific signal 
was apparent when the −219G oligomer was used to probe PC12 nuclear extracts, when −219T 
was used to probe PC12 extracts (lanes 10–12), interactions appeared at “III” and “IV”. This 
interaction was blocked by unlabeled −219T but not by unlabeled −219G oligomer. This 
indicates that a DNA-protein interaction existed with PC12 nuclear extract to the −219T 
oligomer, and it is specific to the “T” state of the polymorphism but is not present with the 
polymorphism’s “G” state in a rodent nuclear extract. Migration rates may be similar enough to 
consider “I” and “III” to be the same bands as “II” and “IV”. 
Southwestern blotting of APOE polymorphisms. Nuclear extracts (10µg) from PC12 and NB 
cells were subject to 10% SDS–PAGE and blotted to nitrocellulose. Uniformity of transfer was 
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assessed by temporary staining with Ponceau S (Fig. 9A). The double–stranded oligomers that 
were used for EMSA were also used to probe the nitrocellulose membranes for southwestern 
blotting. Assays were done in duplicate and figures are representative of results. Southwestern 
blotting with the −491A, −491T, −219G, and −219T probes produced at least one band with each 
probe in both NB and PC12 nuclear extracts (Fig. 9B). Oligomers for the −491 A/T 
polymorphism had different binding patterns in PC12 and NB extracts, and these patterns 
differed between “A” and “T” variants (Fig. 9B). In PC12 extracts, the “A” variant bound a 
protein at approximately 60–70 kDa, while the “T” variant lacked this binding. In contrast to the 
“A” SNP, “T” bound a protein that ran at approximately 30 kDa. In NB extracts, both −491 
variants strongly interacted with a protein at approximately 125 kDa, and the “T” variant had an 
additional interaction at approximately 30 kDa. 
 The −219 G/T polymorphic oligomers also had different binding patterns between PC12 
and NB nuclear extracts, and differences existed between “G” and “T” variants (Fig. 9B). 
Specifically, in PC12 extracts, the “G” variant had a distinct interaction at approximately 30 kDa 
with a possible much weaker interaction at approximately 60–70 kDa, while the “T” variant 
interacted at 60–70 kDa. In NB nuclear extracts, both “G” and “T” variants interacted with a 
protein at approximately 125 kDa, while the “G” variant had an additional interaction at 
approximately 30 kDa. 
Alterations of predicted TF sites around the APOE polymorphisms. When sequences 
flanking each polymorphism were used to further probe the TransFac database, substituting 
minority polymorphic variant alleles at −491 (A→T), −427 (T→C), and −219 (G→T), several 
interesting predictions came to light. The 20 bp region between −481/−501 was predicted to gain 
likely binding sites for GATA–1, –2, and –3, while losing potential binding sites for p300, RXR–
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α, SP1, and SRY with the A→T polymorphism. The −417/−437 region was predicted to lose no 
putative binding sites while gaining AP–1, GC box, SP1, and T–Antigen binding sites with the 
T→C polymorphism. The −209/−229 region was predicted to lose Bcd, E47/Th1, GATA, LBP–
1, and Prd sites while gaining a Cdx–1 site with the G→T polymorphism. 
Discussion 
The ε4 APOE genotype is the strongest known genetic risk factor for AD. This genotype instills 
gain of function in the ApoE protein that corresponds to increased accumulation of Aβ peptide. 
Our underlying hypothesis is that increased expression of a lower risk factor genotype (e.g., ε3) 
can give analogous results to gain of function, upon the presumption that the function “gained” 
actually exists in the lower–risk phenotype, albeit operating at significantly lower efficiency. 
Association studies between ApoE levels and Aβ accumulation support this hypothesis (Lambert 
et al. 2005). Selected APOE promoter SNPs, specifically occurring at −491 (A/T), −427 (T/C), 
and −219 (G/T) have been variously shown to potentially associate, independently or in tandem 
with each other, with incidence of AD (Belbin et al. 2007). Meta–analysis of 38 studies indicated 
an AD–associated OR (95% CI) of 0.73 (0.64, 0.82) for the T allele at −491; meta–analysis of 13 
studies showed an OR (95% CI) of 0.86 (0.68, 1.09) for the C allele at −427; and meta–analysis 
of 20 studies revealed an OR (95% CI) of 0.73 (0.68, 0.78) for the G allele at −217 (Bertram et 
al. 2007). Specific mechanisms of these SNPs have been previously investigated in cell culture 
and EMSA studies (Artiga et al. 1998b; Bullido et al. 1998). These studies were done in hepatic 
cell lines and determined that the −491A polymorphic variant drove higher reporter expression 
than did −491T, but only in a single clone pair, not a full battery of possible variants. The 
previous studies also determined that the −219G variant drove greater reporter expression than 
did −219T, again only with a single clone pair. 
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In the population tested herein of 735 individuals, 310 of whom were diagnosed with 
sporadic AD, we determined that homozygosity for the −491A allele and for the −219T allele 
associated with significant risk (OR 1.55 and OR 1.64, respectively) of sporadic AD. After 
stratification for the presence of the ε4 allele, the −491AA genotype remained a risk factor for 
AD among non–ε4 subjects. (OR 1.58). 
We further investigated these SNPs’ responses in human neuroblastoma (NB) and rat 
neuronal (PC12) cells. In addition, we considered potential interactions between and among each 
polymorphic state. We have determined that the −491A variant independently produced greater 
levels of reporter protein than did the −491T variant in both NB and PC12 cell cultures. This 
corresponds to other studies that have linked the −491A variant to greater levels of ApoE in vivo 
(Laws et al. 2002) and in vitro (Artiga et al. 1998a) and to greater risk of AD (Casadei et al. 
1999; Lambert et al. 2002; Lambert et al. 2004). These elements are summarized in Fig. 10. 
Briefly, our reporter assays determined that the −491A variant resulted in higher levels of 
reporter protein while −491T corresponded to lower reporter levels. In our own data, −491AA 
genotype corresponded to greater risk of AD when our sample was stratified for APOEε4 status. 
On the other hand, while we did observe a correspondence between −219 G/T CAT reporter 
fusion clone construction and reporter gene product levels, we did not observe a corresponding 
APOEε4–stratified AD risk (Fig. 11C–D). However, it should be noted that the −491AA 
genotype has also been associated with reduced levels of ApoE in vivo (Roks et al. 2002). In 
addition, other studies have failed to find linkage between the −491 A/T SNP and effects on AD 
frequency (Roks et al. 1998; Toji et al. 1999). 
In addition to effects in cell culture due to −491 A/T, our work herein has shown that the 
−219G variant independently produced greater levels of reporter protein in NB cells, but not in 
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PC12 cells. The −219G polymorphism has been shown to associate with increased (Beyer et al. 
2002) risk of AD in some populations, but other studies have shown that the T allele is 
associated with increased AD risk (Lambert et al. 2002; Lambert et al. 2004). In addition, 
multiple ANOVA of our data indicated interactive effects between the −491 A/T and −219 G/T 
alleles. A previous study by other workers has determined that the −491A/−219T “haplogroup” 
may confer AD risk (Lambert et al. 2004) and that these SNPs may work in vivo as a 
“haplogroup” more strongly than they do as independent alleles (Parra-Bonilla et al. 2003). Such 
behavior would be similar to risk conferred by two promoter polymorphisms we have previously 
studied in the APP promoter (Lahiri 2004b; Lahiri et al. 2005). Combination of our reporter 
assay results with our analysis of potential changes in transcription factor binding sites at these 
two polymorphic sites suggests a model that may explain both our results and those noted by 
Lambert’s group (Fig. 11). Briefly, the −419A variant is predicted to have greater affinity for 
SP1 than does −491T, while −219G is predicted to have greater affinity for GATA family factors 
than does −219T. If the combination is −491A/−219T, SP1 binding drives greater expression of 
the APOE gene, resulting in greater risk of AD. On the other hand, our reporter assay determined 
nearly equal levels of reporter protein for both −491A/−219G and −419T/−219G. In this case, 
GATA factor(s) binding to the −219 site “override” the more distal site in regulation of the 
APOE gene promoter. When both sites are low affinity, as in −491T/−219T, then the APOE 
promoter would lack either additional stimulus, predicting lower levels of ApoE and reduced risk 
of AD. This model does not explain the behavior of −219 oligomers in EMSA with PC12 nuclear 
extracts. We have elsewhere investigated potentially important differences in human APOE 
promoter activity in human vs. rodent cell cultures and extracts (Maloney et al. 2007). As AD is 
a human disorder, we have given preference to results found with NB extracts in our model. 
Three polymorphisms in human APOE promoter 
Maloney et al 18 
The SP1 transcription factor has been determined to be present in SK–N–SH cells 
(Carrillo et al. 1999), and the GATA2, GATA3, GATA4, and GATA6 factors (Aoyama et al. 
2005) are highly expressed in several neuroblastoma cell lines. Likewise, SP1 (Atkins et al. 
2003; Nguyen et al. 2005) and GATA factors have been determined to be active in PC12 cells 
(Jia and Takimoto 2003; Lange-Dohna et al. 2003). 
Based on the functional and southwestern blotting results, we suggest that loss of 
function in −491T may be due to loss of SP1 binding or altered affinity to an alternatively 
spliced form of SP1, which may be found in PC12 cells. This explanation would not suffice to 
explain activity changes for −219T due to loss of binding for another important TF of 30–32 kDa 
(most likely GATA2 or 4). However, it has been previously shown that GATA1 acted in 
apparent cooperation with SP1 at the pyruvate kinase promoter and Tal–1 gene (Gregory et al. 
1996) and that GATA4 and GATA6 interact directly with SP1 in modulation of tissue–specific 
transcription of the cytochrome P450c17 gene (Fluck and Miller 2004). 
In PC12 extracts, the −491“A” variant bound a protein at approximately 60–70 kDa, 
while the −491“T” variant lacked this binding. This band may correspond to an alternatively 
spliced form of SP1 transcription factor, though SP1 is typically found to be a higher molecular 
weight protein (>110 kDa) (Thomas et al. 2007). In contrast to the “A” variant, the “T” variant 
bound a protein that migrated at approximately 30 kDa, which may correspond to the predicted 
gain of a GATA binding site. In NB extracts, both −491 variants strongly interacted with a 
protein at approximately 125 kDa, and the “T” variant had an additional interaction at 
approximately 30 kDa, again corresponding to a predicted gain of a GATA binding site. 
However, these binding experiments were not repeated with unlabled −491 or −219 oligomers, 
leaving the specificity of these interactions unanswered. 
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We are, therefore, cognizant that our case in this paper for SP1 as the critical 
transcription factor in the activity of these APOE promoter polymorphisms is primarily 
circumstantial, based upon gel migration rates and predicted binding site affinity. The SP1 
transcription factor may be further implicated if evaluated in the broader context of AD–related 
protein expression. We have previously determined that SP1 and the amyloid β precursor protein 
(APP) co–localize in both mouse and monkey brain regions (Brock et al. 2008). In addition, 
lifespan studies of SP1 and APP expression show that both genes’ mRNA levels tightly mirror 
each other in both mice and monkeys (Wu et al, manuscript in preparation) 
The APOE ε4 polymorphism is a gain–of–function variant, with chaperone activity that 
brings about plaque formation from oligomers of Aβ (Ma et al. 1994), however, gain–of–
function variant may be effectively mimicked by increase of “non–functional” variant levels if 
the “non–functional” variant actually has some small level of the function in question. We 
propose an explanation of the independent activity of the −491AA genotype in increasing AD 
risk in non–APOEε4 individuals. Specifically, the −491A allele is preferentially activated by the 
SP1 transcription factor over the −491T variant. This activation leads to increased levels of 
APOE gene transcription and of ApoE protein. When an individual’s APOE genotype lacks the 
ε4 allele, a “double dose” of increased APOE expression, via SP1 activation of −491AA 
genotype, would still result in sufficiently greater amounts of APOE gene expression to partially 
“make up for” deficiency of APOEε4 chaperone activity. However, this “de facto gain–of–
function” would still not be equivalent to the true gain–of–function found in ApoE ε4 protein, 
which accounts for the lower, albeit still significant, increase in risk for AD found in −491AA 
individuals. There is increasing evidence that cholesterol plays a role in AD pathology, perhaps 
through its effects on amyloid deposition (Pappolla et al. 2003; Sparks et al. 2002; Sparks et al. 
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1994). Furthermore, elevated low–density lipoprotein (LDL) levels correspond to greater brain 
amyloid β peptide deposition (Kuo et al. 1998). Likewise, study of an African population 
determined an association between higher levels of cholesterol and LDL and AD risk in 
individuals who lack the APOEε4 genotype. In essence, we suggest that total levels of ApoE, 
and by extension, levels of LDL, and levels of circulating lipids in general, have an important 
influence on lifetime risk of developing AD for the majority of cases of the disease, specifically 
sporadic AD in individuals lacking the APOEε4 genotype. 
This hypothesis would lead to parallel consideration of gene–environment interactions 
potentially influencing the effect of a promoter polymorphism. On the one hand, gene expression 
could be acutely perturbed due to inflammation, nutritional fluctuation, or stress. However, 
environment can also alter gene expression in a long–term fashion. One manner in which this can 
occur is by induction of a somatic epitype—persistent, non–heritable alterations in DNA 
methylation and/or oxidation in response to extrinsic factors, such as exposure to lead (Pb) 
(Lahiri and Maloney 2006). Pb exposure has further been determined to alter levels of SP1 in a 
latent early–life regulation (LEARn) fashion (Lahiri et al. 2007). It should be noted that Pb 
exposure and APOE genotype have been found to interact in development of central nervous 
system toxicity (Stewart et al. 2002), and Pb was the specific agent determined to influence SP1 
and APP levels in a LEARn fashion in two recently–studied species, mice and monkeys (Basha 
et al. 2005; Wu et al. 2008). This suggests a further possibility that variation in an SP1 site, such 
as found at the APOE −491 A/T polymorphism, could be a factor in individual response to 
stressors such as Pb exposure potentially altering APOE levels, resulting in a similar effect to the 
Pb/APOE genotype interaction. This would present another avenue whereby variations in APOE 
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gene promoter sequences would be influenced by environment, explaining the “incomplete” 
affect that the APOE promoter polymorphisms have been observed to have on incidence of AD. 
Since the cell culture in the present work is carried out with PC12 and SK–N–SH cells, 
we briefly argue for their utility as CNS/neuronal cellular models. Our recent work (Ge et al. 
2004; Maloney et al. 2007) has shown distinct similarities of DNA–nuclear protein interactions 
for portions of the APP and APOE promoters, respectively, in PC12 and SK–N–SH cell nuclear 
extracts vs. both mouse and, importantly, post-mortem human brain cell nuclear extracts. In 
addition, several workers have shown that these cell lines express APP, synaptic proteins, and 
the secretases. However, even if these cells are accepted as suitable stand-ins for CNS neuronal 
cells, the valid issue can be raised that neurons do not typically express ApoE unless injured. We 
contend that pre–AD conditions are a type of stress or injury to neurons, which could cascade 
into full–blown AD, in part through altered expression of the APOE gene, thereby validating the 
use of neuronal cultures to study APOE expression in the context of AD etiology. 
In addition, there is currently no complete model of AD available. Even most transgenic 
animal models do not use the “native” promoters of AD–associated genes. Instead, high–
throughput promoters, such as the promoter of the human prion protein PrP, are used to ensure 
certain and rapid development of AD–like symptoms in the animal. 
Our study is also unique in that it does not solely measure effects of individual alleles on 
expression, but also potential interactions between and among the three polymorphic sites, some 
of which interactions we have found to be significant by reporter expression assay. Likewise, 
most of the studies of these polymorphic sites have used a European population, while ours used 
a USA population, extending the size of the genetic pool from which all studies of these 
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polymorphisms are drawn. It also examines allele effects at the population, expression, and 
DNA–protein interaction levels. 
Acknowledgements This work was supported by the Alzheimer’s Association [to DKL]; 
National Institutes of Health [grant numbers AG18379, AG18884 to DKL]; and the Ministerio 
de Educación y Ciencia [grant number SAF2006-00724 to JP–T]. We gratefully acknowledge 
the advice and help from Dennis Dickson and Clare Ellis, Mayo Clinic, Jacksonville, FL. 
Three polymorphisms in human APOE promoter 
Maloney et al 23 
 
REFERENCES 
 
Aoyama M, Ozaki T, Inuzuka H, Tomotsune D, Hirato J, Okamoto Y, Tokita H, Ohira M, 
Nakagawara A. 2005. LMO3 interacts with neuronal transcription factor, HEN2, and acts 
as an oncogene in neuroblastoma. Cancer Res 65(11):4587-97. 
Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, Garcia MA, Lendon CL, Han SW, Morris 
JC, Vazquez J et al. 1998a. Risk for Alzheimer's disease correlates with transcriptional 
activity of the APOE gene. Hum Mol Genet 7(12):1887-92. 
Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J, Vazquez J, Valdivieso F. 
1998b. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E 
gene. FEBS Lett 421(2):105-8. 
Atkins DS, Basha MR, Zawia NH. 2003. Intracellular signaling pathways involved in mediating 
the effects of lead on the transcription factor Sp1. Int J Dev Neurosci 21(5):235-44. 
Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK, Zawia NH. 2005. 
The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of 
amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25(4):823-9. 
Belbin O, Dunn JL, Ling Y, Morgan L, Chappell S, Beaumont H, Warden D, Smith DA, 
Kalsheker N, Morgan K. 2007. Regulatory region single nucleotide polymorphisms of the 
apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease. Hum Mol 
Genet 16(18):2199-208. 
Three polymorphisms in human APOE promoter 
Maloney et al 24 
Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. 2007. Systematic meta-analyses of 
Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 
39(1):17-23. 
Beyer K, Lao JI, Gomez M, Riutort N, Latorre P, Mate JL, Ariza A. 2002. The Th1/E47cs-G 
apolipoprotein E (APOE) promoter allele is a risk factor for Alzheimer disease of very 
later onset. Neurosci Lett 326(3):187-90. 
Brock B, Basha MR, DiPalma K, Anderson A, Harry GJ, Rice DC, Maloney B, Lahiri DK, 
Zawia NH. 2008. Co–localization and Distribution of Cerebral APP and SP1 and its 
Relationship to Amyloidogenesis. J Alzheimers Dis 13(1):71-80. 
Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, Lendon C, Han SW, Morris 
JC, Frank A et al. 1998. A polymorphism in the regulatory region of APOE associated 
with risk for Alzheimer's dementia. Nat Genet 18(1):69-71. 
Carrillo C, Cisneros B, Montanez C. 1999. Sp1 and AP2 transcription factors are required for the 
human fragile mental retardation promoter activity in SK-N-SH neuronal cells. Neurosci 
Lett 276(3):149-52. 
Casadei VM, Ferri C, Veglia F, Gavazzi A, Salani G, Cattaneo M, Sorbi S, Annoni G, Licastro 
F, Mariani C et al. 1999. APOE-491 promoter polymorphism is a risk factor for late-
onset Alzheimer's disease. Neurology 53(8):1888-9. 
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, 
Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the 
risk of Alzheimer's disease in late onset families. Science 261(5123):921-3. 
Crook R, Hardy J, Duff K. 1994. Single-day apolipoprotein E genotyping. J Neurosci Methods 
53(2):125-7. 
Three polymorphisms in human APOE promoter 
Maloney et al 25 
Du Y, Chen X, Wei X, Bales KR, Berg DT, Paul SM, Farlow MR, Maloney B, Ge Y-W, Lahiri 
DK. 2005. NF-kappaB mediates amyloid beta peptide-stimulated activity of the human 
apolipoprotein E gene promoter in human astroglial cells. Brain Res Mol Brain Res 
136(1-3):177-188. 
Fluck CE, Miller WL. 2004. GATA-4 and GATA-6 modulate tissue-specific transcription of the 
human gene for P450c17 by direct interaction with Sp1. Mol Endocrinol 18(5):1144-57. 
Ge Y-W, Ghosh M, Song W, Maloney B, Lahiri D. 2004. Mechanism of promoter activity of the 
beta-amyloid precursor protein gene in different cell types. Identification of a specific 30 
bp fragment in the proximal promoter region. J Neurochem 90(6):1432-44. 
Ghosh C, Song W, Lahiri DK. 2000. Efficient DNA transfection in neuronal and astrocytic cell 
lines. Mol Biol Rep 27(2):113-121. 
Gregory RC, Taxman DJ, Seshasayee D, Kensinger MH, Bieker JJ, Wojchowski DM. 1996. 
Functional interaction of GATA1 with erythroid Kruppel-like factor and Sp1 at defined 
erythroid promoters. Blood 87(5):1793-801. 
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. 2003. Alzheimer disease in the US 
population: prevalence estimates using the 2000 census. Arch Neurol 60(8):1119-22. 
Jia Y, Takimoto K. 2003. GATA and FOG2 transcription factors differentially regulate the 
promoter for Kv4.2 K(+) channel gene in cardiac myocytes and PC12 cells. Cardiovasc 
Res 60(2):278-87. 
Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE. 
1998. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 
1-42 levels. Biochem Biophys Res Commun 252(3):711-5. 
Three polymorphisms in human APOE promoter 
Maloney et al 26 
Lahiri DK. 1998. An region upstream of the gene promoter for the beta-amyloid precursor 
protein interacts with proteins from nuclear extracts of the human brain and PC12 cells. 
Brain Res Mol Brain Res 58(1-2):112-122. 
Lahiri DK. 2004a. Apolipoprotein e as a target for developing new therapeutics for Alzheimer's 
disease based on studies from protein, RNA, and regulatory region of the gene. J Mol 
Neurosci 23(3):225-34. 
Lahiri DK. 2004b. Functional characterization of APP regulatory elements: rationale for the 
identification of genetic polymorphism. Ann N Y Acad Sci 1030(1):282-288. 
Lahiri DK, Alley GM, Ge YW, Du Y. 2002. Functional characterization of the 5'-regulatory 
region of the murine apolipoprotein gene. Ann N Y Acad Sci 973:340-344. 
Lahiri DK, Lewis S, Farlow MR. 1994. Tacrine alters the secretion of the beta-amyloid precursor 
protein in cell lines. J Neurosci Res 37(6):777-787. 
Lahiri DK, Maloney B. 2006. Genes are not our destiny: the somatic epitype bridges between the 
genotype and the phenotype. Nat Rev Neurosci 7:doi:10.1038/nrn2022-c1. 
Lahiri DK, Maloney B, Basha MR, Ge YW, Zawia NH. 2007. How and when environmental 
agents and dietary factors affect the course of Alzheimer’s disease: the “LEARn” model 
(Latent Early Associated Regulation) may explain the triggering of AD. Curr Alzheimer 
Res 4(2):219-228. 
Lahiri DK, Nurnberger JI, Jr. 1991. A rapid non-enzymatic method for the preparation of HMW 
DNA from blood for RFLP studies. Nucleic Acids Res 19(19):5444. 
Lahiri DK, Wavrant De-Vrieze F, Ge Y-W, Maloney B, Hardy J. 2005. Characterization of two 
APP gene promoter polymorphisms that appear to influence risk of late-onset 
Alzheimer's disease. Neurobiol Aging 26(10):1329-1341. 
Three polymorphisms in human APOE promoter 
Maloney et al 27 
Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C, Wang JC, Bullido MJ, Harris JM, 
Artiga MJ, Hernandez D, Kwon JM et al. 2002. Contribution of APOE promoter 
polymorphisms to Alzheimer's disease risk. Neurology 59(1):59-66. 
Lambert JC, Berr C, Cottel D, Amouyel P, Helbecque N. 2004. APOE promoter polymorphisms 
and dementia in the elderly. Neurosci Lett 365(2):116-9. 
Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Perez-Tur J, Mouroux V, 
Mohr M, Cecyre D et al. 1998. Pronounced impact of Th1/E47cs mutation compared 
with -491 AT mutation on neural APOE gene expression and risk of developing 
Alzheimer's disease. Hum Mol Genet 7(9):1511-6. 
Lambert JC, Mann D, Richard F, Tian J, Shi J, Thaker U, Merrot S, Harris J, Frigard B, Iwatsubo 
T et al. 2005. Is there a relation between APOE expression and brain amyloid load in 
Alzheimer's disease? J Neurol Neurosurg Psychiatry 76(7):928-33. 
Lange-Dohna C, Zeitschel U, Gaunitz F, Perez-Polo JR, Bigl V, Rossner S. 2003. Cloning and 
expression of the rat BACE1 promoter. J Neurosci Res 73(1):73-80. 
Laws SM, Clarnette RM, Taddei K, Martins G, Paton A, Hallmayer J, Almeida OP, Groth DM, 
Gandy SE, Forstl H et al. 2002. APOE-epsilon4 and APOE -491A polymorphisms in 
individuals with subjective memory loss. Mol Psychiatry 7(7):768-75. 
Ma J, Yee A, Brewer HB, Jr., Das S, Potter H. 1994. Amyloid-associated proteins alpha 1-
antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into 
filaments. Nature 372(6501):92-4. 
Maloney B, Ge Y-W, Alley GM, Lahiri DK. 2007. Important Differences between human and 
mouse APOE gene promoters with implications for Alzheimer’s disease. J Neurochem 
103(3):1237-1257. 
Three polymorphisms in human APOE promoter 
Maloney et al 28 
Nguyen HN, Lee SY, Hwang DY, Kim YK, Yuk DY, Lee JS, Hong JT. 2005. Decrease in NF-
kappaB, AP-1 and SP-1 activities in neuronal cells expressing presenilin 2. Neuroreport 
16(7):731-5. 
Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones 
X, Henry TL, Matsubara E, Zambon D et al. 2003. Mild hypercholesterolemia is an early 
risk factor for the development of Alzheimer amyloid pathology. Neurology 61(2):199-
205. 
Parra-Bonilla G, Arboleda G, Yunis J, Solano E, Pardo R, Arango G, Hedmont D, Arboleda H. 
2003. Haplogroup analysis of the risk associated with APOE promoter polymorphisms (-
219T/G, -491A/T and -427T/C) in Colombian Alzheimer's disease patients. Neurosci Lett 
349(3):159-62. 
Ramos MC, Matias S, Artiga MJ, Pozueta J, Sastre I, Valdivieso F, Bullido MJ. 2005. Neuronal 
specific regulatory elements in apolipoprotein E gene proximal promoter. Neuroreport 
16(9):1027-30. 
Roks G, Cruts M, Bullido MJ, Backhovens H, Artiga MJ, Hofman A, Valdivieso F, Van 
Broeckhoven C, Van Duijn CM. 1998. The -491 A/T polymorphism in the regulatory 
region of the apolipoprotein E gene and early-onset Alzheimer's disease. Neurosci Lett 
258(2):65-8. 
Roks G, Cruts M, Houwing-Duistermaat JJ, Dermaut B, Serneels S, Havekes LM, Hofman A, 
Breteler MM, Van Broeckhoven C, van Duijn CM. 2002. Effect of the APOE-491A/T 
promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The 
Rotterdam Study. Am J Med Genet 114(5):570-3. 
Three polymorphisms in human APOE promoter 
Maloney et al 29 
Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, 
Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ et al. 1993. Association of 
apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's 
disease. Neurology 43(8):1467-72. 
Sparks DL, Lochhead J, Horstman D, Wagoner T, Martin T. 2002. Water quality has a 
pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid beta 
(Abeta) in rabbit brain. J Alzheimers Dis 4(6):523-529. 
Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T, Gross DR. 1994. Induction of 
Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary 
cholesterol. Exp Neurol 126(1):88-94. 
Stewart WF, Schwartz BS, Simon D, Kelsey K, Todd AC. 2002. ApoE genotype, past adult lead 
exposure, and neurobehavioral function. Environ Health Perspect 110(5):501-5. 
Thomas K, Wu J, Sung DY, Thompson W, Powell M, McCarrey J, Gibbs R, Walker W. 2007. 
SP1 transcription factors in male germ cell development and differentiation. Mol Cell 
Endocrinol 270(1-2):1-7. 
Thome J, Gewirtz JC, Sakai N, Zachariou V, Retz-Junginger P, Retz W, Duman RS, Rosler M. 
1999. Polymorphisms of the human apolipoprotein E promoter and bleomycin hydrolase 
gene: risk factors for Alzheimer's dementia? Neurosci Lett 274(1):37-40. 
Toji H, Maruyama H, Sasaki K, Nakamura S, Kawakami H. 1999. Apolipoprotein E promoter 
polymorphism and sporadic Alzheimer's disease in a Japanese population. Neurosci Lett 
259(1):56-8. 
Tycko B, Lee JH, Ciappa A, Saxena A, Li CM, Feng L, Arriaga A, Stern Y, Lantigua R, 
Shachter N et al. 2004. APOE and APOC1 promoter polymorphisms and the risk of 
Three polymorphisms in human APOE promoter 
Maloney et al 30 
Alzheimer disease in African American and Caribbean Hispanic individuals. Arch Neurol 
61(9):1434-9. 
Wu J, Basha MR, Brock B, Maloney B, Cox D, Harry J, Cardozo-Paleaz F, Rice DC, Lahiri DK, 
Zawia NH. 2008. Alzheimer's disease (AD)-like pathology in aged monkeys after 
infantile exposure to environmental metal lead (Pb): evidence for a developmental origin 
and environmental link for AD. J Neurosci 28(1):3-9. 
Zurutuza L, Verpillat P, Raux G, Hannequin D, Puel M, Belliard S, Michon A, Pothin Y, 
Camuzat A, Penet C et al. 2000. APOE promoter polymorphisms do not confer 
independent risk for Alzheimer's disease in a French population. Eur J Hum Genet 
8(9):713-6. 
 
Legends to Figures 
Fig. 1. Construction of expression–cassette clones containing three single–nucleotide 
polymorphisms in the APOE promoter sequence. A) Schematic diagram of a 1.4kb PCR 
fragment of the APOE gene (small arrows indicate locations of PCR primers), including the 5’–
UTR and 1kb of promoter, and a fragment of the first intron of the gene, as produced by PCR 
from human genomic DNA samples. Three single–nucleotide polymorphic sites (Artiga et al. 
1998b; Bullido et al. 1998; Lambert et al. 2002) are indicated (−491, −427, and −219) in 
relationship to the transcription start site (+1). An active NF–κB site (Du et al. 2005) and 
promoter activity domains (Maloney et al. 2007) (HuA—“human A”—through HuE) are also 
indicated. B) The 1.4kb fragment was cloned into the KpnI and XhoI sites of pBluescript SK (−). 
C) The pBluescript–backbone clone was digested with KpnI and XhoI, and the 1.4kb APOE 
fragment was subcloned into the KpnI/XhoI sites of pGL3Basic. D) The pGL3Basic–backbone 
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clone was digested with KpnI and XhoI, and the 1.4kb APOE fragment was cloned into the 
KpnI/XhoI sites of pCAT3Basic. E) Eight different haplotype APOE promoter–CAT expression 
gene clones were generated and subsequently used for DNA transfection studies. 
Fig. 2. Effects of individual single–nucleotide polymorphism on reporter levels in NB cells. 
APOE promoter polymorphism–CAT reporter fusion clones were transfected into NB cells as 
described. Cell lysates were extracted and reporter protein levels measured by ELISA. Data was 
grouped in three ways, according to the state of each individual polymorphism. All APOE–
derived clones drove reporter levels significantly higher than empty pCAT3–basic backbone. 
“N” refers to either variant at the non–specified polymorphism locus. The top portion of each 
figure schematically depicts locations of SNPs with respect to the APOE promoter. A) −491 A/T 
polymorphism. Each state was significantly different from the other. B) −427 T/C 
polymorphism. Neither state differed significantly from the other. C) −219 G/T polymorphism. 
Each state was significantly different from the other. 
Fig. 3. Interactions between any two of three APOE promoter polymorphisms in NB cells. 
Reporter level activity data from APOE promoter polymorphism–CAT reporter fusion clones 
transfected in NB cells were combined according to any two polymorphic sites. “N” refers to 
either variant at the non–specified polymorphism locus. A) Activity of clones arranged according 
to specific −491/−219 combination. Combinations that share statistical symbols do not 
significantly differ from each other. B) Activity of clones arranged according to specific 
−491/−427 combination. Combinations that share statistical symbols do not significantly differ 
from each other. C) Activity of clones arranged according to specific −427/−219 combination. 
Combinations that share statistical symbols do not significantly differ from each other. 
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Fig. 4. Reporter protein levels of APOE promoter polymorphism triplet–CAT fusion clones 
in NB cells. A) Reporter level activity data from APOE promoter polymorphism–CAT reporter 
fusion clones were combined according to all three polymorphic sites. Data was analyzed by 
Waller–Duncan multiple range test as described in the text. Individual combination of each of 
two states for 3 polymorphic sites (8 total combinations) is shown. Combinations that share 
statistical symbols do not significantly differ from each other. B) “Slice” of reporter protein 
levels according to state of −427 polymorphic site. Similarity of response “curves” between 
states indicates that effect of the −427 polymorphism on the overall system is very low. 
Fig. 5. Effects of individual single–nucleotide polymorphism on reporter levels in PC12 
cells. APOE promoter polymorphism–CAT reporter fusion clones were transfected into PC12 
cells as described. Cell lysates were extracted and reporter levels measured by ELISA. Data was 
grouped in three ways, according to the state of each individual polymorphism. All APOE–
derived clones drove reporter protein levels significantly higher than empty pCAT3–basic 
backbone. “N” refers to either variant at the non–specified polymorphism locus. The top portion 
of each figure schematically depicts locations of SNPs with respect to the APOE promoter. A) 
−491 A/T polymorphism. Each state was significantly different from the other. B, C) −427 T/C 
and −219 G/T polymorphisms. Neither state within either polymorphism differed significantly 
from the other. 
Fig. 6. Interactions between any two of three APOE promoter polymorphisms in PC12 
cells. Reporter level activity data from APOE promoter polymorphism–CAT reporter fusion 
clones were combined according to any two polymorphic sites. “N” refers to either variant at the 
non–specified polymorphism locus. A) Activity of clones arranged according to specific 
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−491/−219 combination. Combinations that share statistical symbols do not significantly differ 
from each other. B) Activity of clones arranged according to specific −491/−427 combination. 
Combinations that share statistical symbols do not significantly differ from each other. C) 
Activity of clones arranged according to specific −427/−219 combination. Combinations that 
share statistical symbols do not significantly differ from each other. 
Fig. 7. Reporter protein levels of APOE promoter polymorphism triplet–CAT reporter 
fusion clones in PC12 cells. A) Reporter level activity data from APOE promoter 
polymorphism–CAT reporter fusion clones were combined according to all three polymorphic 
sites. Data was analyzed by Waller–Duncan multiple range test as described. Each individual 
combination of states for 3 polymorphic sites (8 total combinations) is shown. Combinations that 
share statistical symbols do not significantly differ from each other. B) “Slice” of reporter protein 
levels according to state of −427 polymorphic site. Similarity of response “curves” between 
states indicates that effect of the −427 polymorphism on the overall system is very low, despite a 
“significant” three–way interaction ANOVA result. 
Fig. 8. Electrophoretic mobility shift assay (EMSA) of APOE promoter polymorphic 
oligomers A) EMSA in NB nuclear extracts. Polymorphic oligomers were synthesized and 
labeled with [γ32P]–ATP as described in the text. Oligomers were incubated with nuclear extracts 
from NB cells as described in the text. Reactions were run on native 5% TGE 
(Tris/Glycine/EDTA)–PAG (polyacrylamide gel) electrophoresis, gel was dried, and subject to 
radiofluorography. Bands corresponding to DNA–protein interactions are indicated; unbound 
probe ran at bottom of gel. B) EMSA in PC12 nuclear extracts. Polymorphic oligomers were 
synthesized and labeled with [γ32P]–ATP. Oligomers were incubated with nuclear extracts from 
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PC12 cells as described in the text. Reactions were run on native 5% TGE–PAG, gel was dried, 
and subject to radiofluorography. EMSA bands are indicated, unbound probe ran at bottom of 
gel. 
Fig. 9. Southwestern blots of APOE promoter polymorphic oligomers in NB and PC12 cell 
nuclear extracts. Nuclear proteins from NB (lanes 3, 4, 7, 8) and PC12 (lanes 1, 2, 5, 6) cells 
were separated via denaturing 10% SDS–PAG electrophoresis and blotted to nitrocellulose. A) 
Blots were stained with Ponceau S and photographed. B) Blots were probed with [γ32P]–ATP 
labeled oligomers for APOE promoter polymorphisms −491A (lanes 1, 3), −491T (2, 4), −219G 
(5, 7), and −219T (6, 8) under renaturing conditions as described in the text. Blots were exposed 
to X–ray film for fluorography. 
Fig. 10. Schematic representation of APOE promoter polymorphism activity. Diagrams 
represent relative activities of each of two APOE promoter polymorphisms (−491 A/T and −219 
G/T) found to be active in our reporter gene assay. A) Activity of −491 A/T polymorphism in NB 
and PC12 cells. Taken together, the −491A clones showed significantly higher expression of 
reporter gene product than did −491T clones. This corresponds with our observation that 
−491AA genotype correlates with increased risk of AD. B) Activity of −219 G/T polymorphism 
in NB cells. Taken together, the −219G clones showed significantly higher expression of reporter 
gene product than did −219T clones. However, associated risk for AD was not independent at the 
−219 G/T polymorphism when stratified for APOEε4 status. 
Fig. 11. Interaction of −491 A/T and −219 G/T polymorphisms. The −219 G/T polymorphism 
did not bring about significant changes in reporter gene product levels in PC12 cells. However, 
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multiple ANOVA revealed interaction between −491 A/T and −219 G/T. Examination of the 
data revealed that the −219T variant appears to “intensify” the effects of −491A vs. T while 
−219G “mutes” this effect. When compared to putative loss or gain of transcription factor 
binding sites, the A) presence of an SP1 site and absence of a GATA site corresponded to 
greatest reporter levels. This corresponded to increased AD risk in “haplogroup” analysis 
performed by other laboratories (Parra-Bonilla et al. 2003). The presence of a GATA site, 
regardless of whether an SP1 site was B) present or C) absent corresponded to intermediate 
levels of CAT reporter product. D) When both sites were absent, CAT reporter levels were 
lowest in our study. 
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